Flavin-containing monooxygenase (FMO)1-4 oxidize methionine (Met) to methionine sulfoxide (MetO). FMO3, the primary isoform expressed in adult human liver, has the lowest K m and favors methionine-d-sulfoxide (Met-d-O) formation over methionine-l-sulfoxide. Because female mice, but not males, also express FMO3 in liver, levels of Met and its major metabolites were determined in male or female mice dosed with 400 mg/kg Met i.p. The results show that Met levels in male and female mouse liver or plasma increased significantly at both 15 and 30 min after the Met treatment; Met plasma and liver levels at 30 min were similar or lower than the corresponding levels at 15 min. Liver and plasma MetO levels increased significantly in both sexes at 30 min, and Met-d-O was the major MetO diastereomer detected. Interestingly, less than 0.1% of the Met dose was excreted in the urine (0-24 h) as Met and Met-d-O. SAdenosylmethionine (SAM) was the major metabolite detected in liver at 15 min. Liver SAM levels at 30 min were lower than the levels at 15 min, and the plasma SAM levels at both 15 and 30 min were much lower than the corresponding levels in the liver.
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Introduction
Flavin-containing monooxygenases (FMOs) are microsomal enzymes that catalyze the NADPH-and O 2 -dependent oxidation of heteroatoms (nitrogen, sulfur, phosphorus) present in the chemical structure of a variety of drugs and xenobiotics. Five functional forms (FMO1-5) have been characterized to date (Ziegler, 2002) . In humans, FMO1 is the primary isoform expressed in neonate liver, but a switch occurs shortly after birth to FMO3, the primary isoform expressed in adult human liver (Koukouritaki et al., DMD #12104 of Met proceeds with the highest affinity and greatest diastereomeric selectivity among FMO1-5.
Stereoselective formation of Met-d-O was also detected in rabbit and rat liver microsomes incubated with Met and exhibited K m and V/K values similar to cDNA expressed FMO3 (Duescher et al., 1994; Krause et al., 1996) . The latter results provided evidence for FMO3 being the primary isoform involved in Met S-oxidation in rabbit and rat liver. Additional experiments also provided evidence that FMOs, but not cytochrome P-450s, peroxidases, or reactive oxygen species, mediated the Met S-oxidase activity (Krause et al., 1996) . Human liver microsomes also had high Met S-oxidase activity with Met-d-O being the major diastereomer formed (Ripp et al., 1999a (Ripp et al., , 1999b . Female mouse liver microsomes, which showed similar Met S-oxidase activity to male and female human liver microsomes exhibited nearly 3-fold higher activity than male mouse liver microsomes. These results indicated that FMO3 plays an important role in Met Soxidation in female mouse and male and female human liver microsomes when Met is present in the millimolar range. Such a range is significantly higher than normal free Met plasma concentrations in healthy humans (40-60 µM) . However, homocystinuric children, patients with alcoholic liver disease, and humans with defects in the Met transmethylation and transsulfuration pathway may exhibit plasma Met levels from 0.1-DMD #12104 6 et al., 1999; Regina et al., 1993 , Shinozuka et al., 1971 , FMO3 S-oxidation of Met may be important in overall Met metabolism and toxicity.
The primary goal of this study was to quantitate MetO formation in the liver, plasma, and urine of male and female mice dosed with 400 mg/kg Met. This dose was selected to raise plasma and liver Met concentrations to levels seen in some humans with impaired Met metabolism. Liver, plasma, and urine levels of potential Met metabolites in several Met metabolic pathways including the Met N-acetylation, transmethylation, and transamination pathways (Figures 1, 2 and 3 respectively) were also determined to assess the relative roles of these pathways in the metabolism of a single high dose of Met.
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Animals. Male and female B6C3F1 mice (18-25 g) were purchased from Harlan Inc.
(Madison, WI). Mice were maintained on a 12-h light/dark cycle and allowed feed and water ad libitum. Each treatment group contained at least 3 animals. Mice were injected i.p. with 400 mg/kg (2681 µmol/kg) Met dissolved in saline (15 µL/g) or saline alone.
This dose was chosen based on the sensitivity of the analytical methods (see below) and an expected recovery of MetO in mouse urine similar to that seen for S-allyl cysteine sulfoxide in rats given S-allyl cysteine (Krause et al., 2002) . Mice were sacrificed after 15, 30, or 60 min using a CO 2 chamber. Liver (0.2 g) and blood samples were obtained and immediately placed on ice. Plasma was separated from blood samples by centrifugation at 4°C in an eppendorf 5417R centrifuge (Hamburg, Germany) at 5000 g for 10 min. Plasma was then removed and placed into a separate vial. In some cases, plasma was combined from two mice to obtain a 300 µL sample. Ice-cold 0.9% NaCl (3:1 vol) was added to liver samples which were then immediately homogenized using an OMNI 2000 homogenizer (Waterbury, CT). Liver and plasma samples were then deproteinated with ice-cold ethanol (3:1) and centrifuged at 5000 g for 10 min in a Beckman J2-21M centrifuge (Beckman Coulter, Inc., Fullerton, CA). The supernatant was removed and taken to dryness as described above. The residue was redissolved in 475 µL H 2 O acidified to pH 2.4 with 1 M H 2 SO 4 . Samples were then filtered with an Acrodisc LC-13 membrane filter (Pall Gelman Sciences, Ann Arbor, MI) before fractionation by HPLC (described below).
This article has not been copyedited and formatted. The final version may differ from this version. For urinary analysis of metabolites, female mouse urine was collected from 0-24 h preand post-dose. Urine was pooled from 2 mice housed in a metabolic cage (Nalgene, Rochester, NY). Urine samples (1 mL) were then deproteinized with 50 µL 6 M H 2 SO 4 and placed on ice for 10 min. Samples were then centrifuged at 3000 rpm for 10 min.
The supernatant was removed and placed into a separate vial. Water (500 µL) was then added to each sample. The supernatant was further purified using a Waters Oasis HLB 1cc (30 mg) extraction column (Milford, MA). The column was activated by washing with 1 mL of 100% methanol and 1 mL of 0.33 M H 2 SO 4 ; 0.5 mL of sample was then loaded. Met, MetO and NAMO were not retained and eluted immediately. NAM was eluted with 0.5 mL of 30% methanol. The process was repeated twice more (0.5 mL sample each time) using new columns to purify the remaining sample (1 mL). NAMcontaining eluents were combined separately from the Met, MetO, and NAMOcontaining eluents. All eluents were then dried as described above.
Semi-preparative HPLC fraction collection of metabolites. An HPLC fraction collecting method was developed to simultaneously separate nine metabolites of interest with the exception of 3-MTPO and Met, which coeluted (Figures 4 and 5) . Two liver samples from each mouse were processed. One liver sample was used to fractionate MetO, Met, NAMO, SAH, 3-MTP, and MTA, and the second liver sample was used to fractionate SAM, 3-MTPO, and 3-MTP. All metabolite fractions in plasma were collected from one plasma sample. Urinary NAM samples were fraction-collected separately from urinary Met, MetO, and NAMO samples. All urine samples were salted out with 1 mg of K 2 SO 4 prior to fraction collecting. HPLC analyses were carried out This article has not been copyedited and formatted. The final version may differ from this version. were eluted using an isocratic gradient. Eluent was collected from 4.8 to 5.6 min (3-MTPO), and 5.8-6.8 min (Met). The fractions were then dried as described above.
Removal of TFA via HPLC fraction collection. Further fraction collecting methods were developed for NAM, NAMO, 3-MTP, and 3-MTPO to remove residual TFA present from the mobile phase of the previous fraction collection step as it was found to react with PBP, the derivatizing reagent used to detect these compounds. Dried liver and plasma NAM or 3-MTP fractions were redissolved in 475 µL H 2 O acidified to pH 2.4 with 1 M H 2 SO 4 . Dried NAMO and 3-MTPO fractions were redissolved in 235 µL acidified H 2 O and combined. NAM and 3-MTP samples were fraction collected as described above using an isocratic gradient of 30% methanol, with its pH adjusted to 2.5 with 1 M H 2 SO 4 . Eluents were collected from 5.6-6.5 min (NAM) or 6.4-7.4 min (3-MTP). The combined NAMO and 3-MTPO sample was fraction collected using an isocratic gradient of 100% H 2 O, with its pH adjusted to 2.5 with 1 M H 2 SO 4 . Eluents were collected from 6.5-7.7 min (3-MTPO) and 7.9-9.3 min (NAMO). NAM, NAMO, and 3-MTPO fractions were then adjusted to pH 5.0 with 0.1 M KOH. 3-MTP fractions were adjusted to pH 7. All fractions were then taken to dryness as described above.
HPLC analysis of NAM and 3-MTP. Using the above designed fraction collecting method utilizing a semi-preparative column, linear standard curves for NAM and 3-MTP were generated in liver and plasma. The limits of quantitation for plasma NAM and 3-MTP were 8 nmol/mL. Liver limits of quantitation were 25 and 12.5 nmol/g liver respectively. Attempts to improve the sensitivity of these methods using PBP This article has not been copyedited and formatted. The final version may differ from this version. derivatization were not successful for liver and plasma (limits of quantitation > 100 nmoles for both metabolites). Urinary NAM was analyzed following PBP derivatization as described below. The limit of quantitation for urinary NAM was 13 nmol/mL urine. (1975) . Briefly, dried NAMO or 3-MTPO-containing fractions were redissolved in 100 µL ACN. The samples were then sonicated thoroughly to ensure complete dissolution of NAMO or 3-MTPO. N-Acetyl-L-leucine (10 µL of a 0.3 mg/mL solution prepared in ACN) was then added to each sample as internal standard. Potassium carbonate (1 mg) was added to each sample followed by sonication for 15 min. An aliquot (75 µL) of each sample was then placed in a vial to which was added 12 µL of PBP. The reaction mixture was heated at 80°C for 30 min. The derivatized products were then analyzed by HPLC with UV detection at 254 nm as described above. The mobile phase on pump A was 1% ACN, with its pH adjusted to 4 with TFA while pump B contained 75% ACN, with its pH adjusted to 4 with TFA.
HPLC analysis of
This article has not been copyedited and formatted. The final version may differ from this version. NAMO was eluted using a gradient method with an initial concentration of 30% B for 6 min. It was then increased to 75% B over 8 min and held for 3 min. The gradient was then decreased to 30% B over 5 min and was held for 3 min for a total run time of 25 min. Retention times for derivatized NAMO and internal standard were 7.7 and 14.3 min respectively. Standard curves for NAMO were generated in liver and plasma and the limits of quantitation were 50 nmol/g (liver) and 33 nmol/mL (plasma). The limit of quantitation for urinary NAMO was 12 nmol/mL.
3-MTPO was eluted using a gradient method with an initial concentration of 55% B for 9 min. It was then increased to 80% B over 5 min and held for 3 min. The gradient was then decreased to 55% B over 5 min and was held for 3 min for a total run time of 25 min. Retention times for derivatized 3-MTPO and internal standard were 5.2 and 11.7 min respectively. Standard curves for 3-MTPO were generated in liver and plasma and the limits of quantitation were 50 nmol/g liver and 33 nmol/mL, respectively. an isocratic gradient of 50 mM sodium phosphate, with its pH adjusted to 3 with TFA.
HPLC analysis of SAM
The retention time for SAM was 4.1 min. For SAH/MTA-containing fractions, pump A was 0.1% TFA, with its pH adjusted to 3 with TFA. Pump B contained 100% methanol.
SAH and MTA were eluted using a gradient method with an initial concentration of 5% B for 5 min. It was then increased to 60% B over 5 min and held for 2 min. The gradient was then decreased to 5% B over 3 min and was held for 3 min for a total run time of 18 min. The retention times for SAH and MTA were 9.7 and 12.9 respectively. Standard curves for SAM, SAH and MTA were generated. The limits of quantitation in liver were 40, 25, and 12.5 nmol/g, respectively. The limit of quantitation in plasma was 4 nmol/mL for all three compounds. Liver Met levels rose to similar levels at 15 min in Met-dosed animals of both sexes and were an average of 15-fold higher in males and 74-fold higher in females compared to saline-dosed mice (Figure 7 ). Plasma Met levels at 15 min were 1.9 ± 0.4 (mean ± SD) mM and 1.7 ± 0.2 mM in Met-dosed males and females, respectively. Met liver levels fell in both males and females by 30 min, though the change was not statistically significant in males (p=0.054). Plasma Met levels at 15 min were not significantly different from those observed at 30 min in either sex (1.5 ± 0.2 mM in males and 1.4 ± 0.1 mM in females). Levels of the Met transmethylation metabolite SAM were higher than any other metabolite monitored in liver in Met-dosed mice at 15 min. SAM levels increased an average of 3-fold over controls in the liver of Met-dosed male mice and 4-fold in Metdosed female mice by 15 min; SAM levels in Met-dosed females were significantly higher than the corresponding levels in Met-dosed males. Liver SAM levels decreased significantly by 30 min in both sexes to nearly half the levels observed at 15 min.
Despite increased liver levels of SAM in dosed mice, there was no significant difference in plasma SAM levels between dosed mice and controls at either determined time point.
Hepatic and plasma SAM levels in either sex at 1 h were not determined.
Liver SAH levels in Met-dosed mice of both sexes were increased 5-10-fold at 15 min, and this increase was still detectable at 30 min in males. Saline-dosed female mice at 30 min had high SAH levels compared to saline-dosed male mice, and these levels were similar to Met-dosed females at 30 min. Because of the high SAH levels in liver of saline-treated female mice at 30 min, female liver SAH levels were also determined at 1 h post-dose. The levels were significantly increased over controls, but had decreased compared to levels at 15 and 30 min post-dose. Significant increases in SAH were also detected in the plasma of dosed mice at 15 and 30 min post-dose in both sexes with plasma SAH levels becoming trace levels at 1 h in females (Figure 8 ).
Liver MTA levels rose 8-fold in Met-dosed males and females by 15 min. MTA levels were still significantly increased over controls at 30 min and 1 h, but decreased by the later time point. Increases in plasma MTA were not detected in either sex.
This article has not been copyedited and formatted. The final version may differ from this version. At 15 min post-dose in liver and plasma in both sexes, approximately 12% of the Met dose was recovered as Met and its metabolites. This is consistent with previous studies indicating that injected Met rapidly accumulates in many organs and tissues including the liver and plasma (Deloar et al., 1997) . In the present study, half of this recovered dose was detected as Met metabolites with conversion to SAM being the primary route for Met metabolism of the pathways examined. Met incorporation into protein is also an important metabolic pathway for Met but was not monitored in the present study (Finkelstein, 1990 , Deloar et al., 1997 . Previously, mice lacking methionine adenosyltransferase 1A (MAT1A), the enzyme that catalyzes the conversion of Met to SAM in the liver, were shown to have 8-fold higher endogenous liver Met levels relative to control mice (Lu et al., 2001) . Large increases in liver SAM levels following a dose of Met have also been reported in guinea pigs and rats (Regina et al., 1992; Shinozuka et al., 1971) . Collectively, these results provide strong evidence for the importance of the transmethylation pathway in Met metabolism in mammals.
The Met transamination metabolites 3-MTP and 3-MTPO were not detected in any of the mouse tissues examined. 3-MTP formation has been detected in rat and (Scislowski et al., 1993; Steele and Benevenga, 1978) . 3-MTP has also been detected in the urine of humans with cystathionine β-synthase deficiency or partial hepatic MAT1A deficiency (Tangerman et al., 2000; Gahl et al., 1988) . Further metabolism of 3-MTP to yield methanethiol has been demonstrated in rats (Scislowski et al., 1993; Finkelstein and Benevenga, 1986) .
Oxidative decarboxylation of KMTB to yield 3-MTPO via 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) has been demonstrated in vitro (Crouch et al., 1997) . Thus, while transamination of Met to KMTB may have occurred, further oxidative decarboxylation of KMTB to 3-MTP or 3-MTPO did not occur to a detectable level in the Met-dosed mice.
NAM, a novel in vivo Met metabolite, was detected in the plasma of Met-dosed female mice at 15 min whereas, of the four male Met-dosed mice at 15 min, two showed increases in NAM that were similar to Met-dosed females and two showed no increase in NAM. Increases in NAM were not detected at 30 min in either sex suggesting that NAM was rapidly excreted or further metabolized. Daabees and colleagues (1984) MetO formation since FMO3 is not expressed in the liver of male mice (Falls et al., 1995; Ripp et al., 1999a) . The highest plasma Met concentration detected in this study (1.9 mM) is also below the K m of FMO3 S-oxidation of Met (3.7-6.5 mM). While FMO3 may have contributed to Met oxidation in female mouse liver, the enzyme responsible for Met oxidation in male mouse liver and the basis for the high levels of Met-d-O detected in both male and female mouse liver and plasma are presently unclear. Ripp et al.
(1999a) detected stereoselective formation of Met-d-O in male mouse liver microsomes incubated with Met despite no immunologically detectable FMO3. However, female mouse liver microsomes showed nearly 3-fold higher Met S-oxidase activity than males whereas, in this study, MetO formation in vivo was similar in both sexes. MetO was also detected in the blood, plasma and urine of children with homocystinuria (Perry et al., DMD #12104 oxidase activity was less diastereoselective than that seen in the present study producing 50-70% of the total MetO formed as Met-d-O. Furthermore, this activity was not detected in male or female mouse liver microsomes. Thus, differences exist in the properties of the in vivo Met S-oxidase activity detected in this study and the high-affinity Met S-oxidase activity previously characterized in vitro.
Non-enzymatic oxidation of Met by multiple mechanisms involving reactive oxygen species may have contributed to the in vivo Met S-oxidase activity (Schoneich, 2005) . Multiple MetO reductases (Msrs) capable of reducing either MetO diastereomer (Vougier et al., 2003; Sharov et al., 1999; Moskovitz et al., 2002) may also have affected the stereochemical composition of MetO detected in mouse tissues. Support for the latter hypothesis is provided by the finding that racemic MetO was as effective in nutrition in rats as Met (Iwami et al., 1992) . This article has not been copyedited and formatted. The final version may differ from this version. 
